Anticoagulant - Open Access .click

Results 171 to 180 of about 222,802 (316)

Anticoagulants and Arteriosclerosis [PDF]

Postgraduate Medical Journal, 1955
openaire +2 more sources

Anticoagulant Therapy in Hospitalized Patients

, 2014
Hospitalized patients who are bed bound are often subject to anticoagulant therapy during admission. There are two common types of therapy used to prevent blood clots: anti-blood clotting devices and chemical substances to prevent blood clots. Anti-blood
Stahl, Chandler Marie
core

Prescribing of Medication to Prevent Glucocorticoid Harms in Patients With Polymyalgia Rheumatica: A Cross‐Sectional Study and Two Emulated Target Trials in the Clinical Practice Research Datalink Aurum

Arthritis &Rheumatology, EarlyView.
Objective Polymyalgia rheumatica (PMR) is a common indication for long‐term glucocorticoid (GC) treatment. Bone‐protective and gastroprotective medications are recommended for those at high risk of adverse events from GCs, but no trials have evaluated their effectiveness in PMR.
Helen Twohig +5 more
wiley +1 more source

Modern Advances in Anticoagulant Therapy

, 2018
Thesis regarding the advances of anticoagulant therapy. This was a literature review which mainly focused on the trials on the Direct acting Oral Anticoagulants (DOACs).
Abdullah, Alend
core

Unveiling Endotypes in Systemic Lupus Erythematosus Through Multiomic Analysis: Insights Into Cardiovascular and Renal Complications

Arthritis &Rheumatology, EarlyView.
Objective Systemic lupus erythematosus (SLE) shows clinical and molecular heterogeneity, and cardiovascular (CV) complications and lupus nephritis (LN) remain leading causes of morbidity and mortality. This study investigated whether omic profiling can reveal molecular endotypes linked to these outcomes.
Tomás Cerdó +84 more
wiley +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Arthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis +22 more
wiley +1 more source

Anticoagulants for Strokes [PDF]

BMJ, 1964
openaire +2 more sources

Higher Complement C4 Gene Copy Number Constitutes a Shared Genetic Risk Factor for Giant Cell Arteritis and IgA Vasculitis

Arthritis &Rheumatology, EarlyView.
Objective Low copy number (CN) of complement C4 isoforms and high CN of retroviral HERV‐K elements are known risk factors for many immune‐mediated inflammatory diseases (IMIDs), often showing sex‐biased effects. Here, we assessed whether CN variation within the C4 gene contributes to giant cell arteritis (GCA) and IgA vasculitis (IgAV), two complex ...
Laura Martínez‐Gutiérrez +295 more
wiley +1 more source

Purification, characterization, and anticoagulant mechanism of an anticoagulant protein from marine <i>Bacillus velezensis</i> B01. [PDF]

Front Microbiol
Yu J +7 more
europepmc +1 more source

RESEARCH OF ANTICOAGULANT ACTIVITY OF MODIFIED POLYSACCHARID

, 2019
The effect of a chemical modified sulfated polysaccharide in experiments on human bloodplasma in vitro on the hemostasis system was studied. The effect of in vitro compounds with various tests on APTT, prothrombin time, and thrombin ...
Nasirov, Kobil Erkinovich +3 more
core

atrial fibrillation
stroke
heparin

venous thromboembolism
thrombosis
rivaroxaban

antiplatelet